Menu
Back to Journals » Drug Design, Development and Therapy » Volume 9
The role of aflibercept in the management of diabetic macular edema
Authors Chang A, Hong T, Ewe YPSY, Bahrami B, Broadhead G
Received 16 April 2015
Accepted for publication 9 June 2015
Published 6 August 2015 Volume 2015:9 Pages 4389—4396
DOI https://doi.org/10.2147/DDDT.S62778
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 4
Editor who approved publication: Professor Shu-Feng Zhou
Andrew A Chang,1–3 Thomas Hong,1,2 Shaun Y Ewe,1,2 Bobak Bahrami,1,2 Geoffrey K Broadhead1–3
1Sydney Institute of Vision Science, 2Sydney Retina Clinic and Day Surgery, 3Save Sight Institute, University of Sydney, Sydney, NSW, Australia
Abstract: Diabetic macular edema (DME) represents one of the leading causes of visual impairment in working-age adults. Although there are several proven treatments available for this condition, pharmacotherapy through the use of intravitreal antivascular endothelial growth factor agents has revolutionized the management of DME over the past decade with superior outcomes compared to laser therapy. This review summarizes the pathophysiology and available treatment options for the management of DME, with an emphasis on the efficacy and safety profile of a single particular intravitreal antivascular endothelial growth factor agent, aflibercept.
Keywords: diabetic macular edema, aflibercept
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.